The Lancet Oncology in conversation with

Rosie Bradley on early-stage breast cancer treatment

The Lancet Oncology

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 4:33

Rosie Bradley (Oxford Population Health, University of Oxford, Oxford, UK) discusses her Article on aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression.

Read the full article:
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv